hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06272825 id: 2023-19/140 briefTitle: Virtual Reality in Patients With Knee Osteoarthritis overallStatus: RECRUITING date: 2024-02-28 date: 2024-07-14 date: 2024-08-14 date: 2024-02-22 date: 2024-02-22 name: Kirsehir Ahi Evran Universitesi class: OTHER briefSummary: One of the main challenges facing the therapist in the treatment of adhesive capsulitis is to motivate the patient throughout conventional therapy. As noted in a recent review, individuals are more interested in leisure activities rather than performing repetitive tasks during therapy. Virtual reality (VR) is a three-dimensional computer-aided programme built with a system that creates virtual reality movements and generates a high amount of visual and sensory feedback during exercise. As a result, virtual reality (VR) has been used in many medical indications and has been shown to promote adherence to treatment by increasing patient motivation. conditions: Knee Osteoarthritis conditions: Pain conditions: Quality of Life studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised controlled primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigator and Outcomes Assessor will be different persons. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Virtual reality name: conventional rehabilitation measure: Visual Analog Scale measure: Visual Analog Scale measure: Visual Analog Scale measure: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measure: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measure: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measure: Biodex Balance System measure: Biodex Balance System measure: Biodex Balance System measure: Short Form 36 (SF36) measure: Short Form 36 (SF36) measure: Short Form 36 (SF36) sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kırşehir Ahi Evran University Faculty of Medicine status: RECRUITING city: Kırşehir state: City Center zip: 40100 country: Turkey name: Basak Cigdem Karacay, Asist Prof role: CONTACT phone: 0905445094803 email: basak.cigdemkaracay@ahievran.edu.tr name: Basak Cigdem Karacay, Asist Prof role: PRINCIPAL_INVESTIGATOR lat: 39.14583 lon: 34.16389 hasResults: False
nctId: NCT06272812 id: IAVI C113 briefTitle: A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in IGRA Positive Adolescents and Adults Living in a TB Endemic Region. overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2028-03 date: 2028-03 date: 2024-02-22 date: 2024-02-22 name: International AIDS Vaccine Initiative class: NETWORK name: Biofabri, SLU name: Universidad de Zaragoza briefSummary: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. conditions: Tuberculosis (TB) studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Double blind whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 4300 type: ESTIMATED name: MTBVAC name: Placebo measure: To evaluate the protective efficacy of of MTBVAC against bacteriologically confirmed pulmonary TB disease, diagnosed by more than one diagnostic test with sputum obtained before initiation of TB treatment as compared to placebo. measure: To evaluate the protective efficacy of one dose of MTBVAC against bacteriologically confirmed pulmonary TB disease, not associated with HIV infection, diagnosed with sputum obtained before initiation of TB treatment, as compared to placebo. measure: To evaluate the protective efficacy of MTBVAC candidate vaccine against definite Xpert MTB/RIF Ultra positive pulmonary TB disease diagnosed with sputum obtained before initiation of TB treatment, as compared to placebo. measure: To evaluate the protective efficacy of one dose of MTBVAC candidate vaccine against clinical TB, as compared to placebo measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the safety and reactogenicity of one dose of MTBVAC candidate vaccine. measure: To assess the immunogenicity of one dose of the MTBVAC candidate vaccine via assessment of humoral and cell-mediated immune (CMI) responses in a subset of the enrolled participants. measure: To assess the immunogenicity of one dose of the MTBVAC candidate vaccine via assessment of humoral and cell-mediated immune (CMI) responses in a subset of the enrolled participants. sex: ALL minimumAge: 14 Years maximumAge: 45 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06272799 id: RS1480/21 briefTitle: Tolerability and Efficacy of Adjuvant T-DM1 in Patients With HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study acronym: ATD overallStatus: RECRUITING date: 2022-09-20 date: 2024-09-20 date: 2024-09-20 date: 2024-02-22 date: 2024-02-22 name: Regina Elena Cancer Institute class: OTHER briefSummary: Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 160 type: ESTIMATED name: T-DM1 adjuvant measure: Evaluate the tolerability. measure: Evaluate the effectiveness of treatment. sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: "Regina Elena" National Cancer Institute status: RECRUITING city: Rome zip: 00144 country: Italy name: Patrizia Vici, Doctor role: CONTACT phone: 06-5266.5584 phoneExt: +39 email: patrizia.vici@ifo.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06272786 id: 2023-18/128 briefTitle: Suprascapular Nerve Block in Patients Rehabilitated After Arthroscopic Rotator Cuff Repair overallStatus: RECRUITING date: 2024-02-28 date: 2024-09-01 date: 2024-10-01 date: 2024-02-22 date: 2024-02-22 name: Kirsehir Ahi Evran Universitesi class: OTHER briefSummary: Suprascapular nerve block is an injection method that has been shown to be effective in shoulder rehabilitation in diseases such as adhesive capsulitis and stroke .. Applying the block under USG guidance instead of blinding increases the effectiveness and reduces complications. conditions: Rotator Cuff Tears conditions: Pain conditions: Nerve Block studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomised controlled primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigator and outcome assessor will be different persons. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 36 type: ESTIMATED name: conventional physiotherapy program. name: Suprascapular nerve block measure: Visual Analog Scale (VAS) measure: Visual Analog Scale (VAS) measure: Visual Analog Scale (VAS) measure: Shoulder joint range of motion (ROM) measure: Shoulder joint range of motion (ROM) measure: Shoulder joint range of motion (ROM) measure: Shoulder Pain and Disability İndex (SPADİ) measure: Shoulder Pain and Disability İndex (SPADİ) measure: Shoulder Pain and Disability İndex (SPADİ) measure: Modified Constant-Murley Scoring measure: Modified Constant-Murley Scoring measure: Modified Constant-Murley Scoring sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ahi Evran University status: RECRUITING city: Kirşehir state: City Centre zip: 40100 country: Turkey name: Basak Cigdem Karacay, Assist Prof role: CONTACT phone: :+90 386 280 39 00 email: basak.cigdemkaracay@ahivran.edu.tr name: Basak Cigdem Karacay, Assist Prof role: PRINCIPAL_INVESTIGATOR lat: 39.14583 lon: 34.16389 hasResults: False
nctId: NCT06272773 id: IRAS Ref: 333663 briefTitle: Forced Oscillation and Breathing Pattern in Asthma overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2025-03 date: 2024-02-22 date: 2024-02-22 name: Karl Sylvester class: OTHER briefSummary: Asthma is a chronic respiratory disease characterised by airway inflammation, bronchoconstriction, and airway hyperresponsiveness. Accurate and reliable assessment of lung function is crucial in diagnosing and monitoring asthma. The forced oscillation technique (FOT) is a non-invasive method that has gained attention in recent years as a valuable tool for evaluating respiratory mechanics in asthma.
FOT involves applying small amplitude oscillations at various frequencies to the respiratory system and measuring the resulting pressure and flow responses. These measurements provide valuable insights into the mechanical properties of the airways, including resistance, compliance, and reactance. FOT offers several advantages over traditional spirometry, such as its ability to assess peripheral airway function, sensitivity to small airway abnormalities, and ease of use, particularly in young children or individuals with severe airflow limitation. FOT also allows for assessment of respiratory mechanics in individuals who may struggle with performing spirometry manoeuvres.
Several studies have demonstrated a high prevalence of Breathing Pattern Disorders (BPDs) in individuals with asthma. These findings suggest that BPDs may be common in asthma and could contribute to the manifestation and severity of respiratory symptoms. Evidence suggests that BPDs can adversely affect pulmonary function in individuals with asthma. One study demonstrated that children with asthma and dysfunctional breathing exhibited significantly reduced forced expiratory volume in one second (FEV1) compared to asthmatics without BPD. This suggests that abnormal breathing patterns may contribute to airflow limitation in asthma, leading to decreased lung function.
We therefore wish to determine the impact of different breathing frequencies on parameters measured using FOT in patients diagnosed with asthma and concomitant obstructive lung function abnormality. conditions: Asthma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 65 type: ESTIMATED name: Forced Oscillation Test measure: Change in airway resistance at 5 Hertz (Hz) and 19Hz sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06272760 id: 2024-02-060 briefTitle: Development of a Remote Therapy Protocol for Upper Limb Function Enhancement in Children With Cerebral Palsy overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-09-30 date: 2026-02-28 date: 2024-02-22 date: 2024-02-22 name: Samsung Medical Center class: OTHER briefSummary: The perpose of this study: Development and demonstration of a teletherapy protocol to improve upper limb function in children with cerebral palsy. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized Controlled Trial primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Single blinding whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Home-based hand-arm bimanual intensive training (Tele-HABIT) name: Hand-arm bimanual intensive training (In-clinic-HABIT) measure: Change from Assisting Hand Assessment (AHA) score at post-intervention test (T1-T0). measure: Change from Baseline Pediatric Motor Activity Log (PMAL) score at post-intervention test (T1-T0). measure: Change from Baseline Melbourne Assessment 2 (MA2) score at post-intervention test (T1-T0). measure: Change from Canadian Occupational Performance Measure (COPM) score at post-intervention test (T1-T0). measure: Change from Pediatric Evaluation of Disability Inventory Computer Adaptive Test (PEDI-CAT) score at post-intervention test (T1-T0). measure: Change from baseline Magnitude ratio (Accelerometer) at post-intervention test (T1-T0). measure: Change from baseline Bilateral magnitude(Accelerometer) at post-intervention test (T1-T0). sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD hasResults: False
nctId: NCT06272747 id: XH-S003-I-101 briefTitle: A Phase I Study of XH-S003 in Healthy Volunteers overallStatus: NOT_YET_RECRUITING date: 2024-02-22 date: 2024-07-30 date: 2024-10-30 date: 2024-02-22 date: 2024-02-22 name: S-Infinity Pharmaceuticals Co., Ltd class: INDUSTRY briefSummary: The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003. conditions: Healthy Adults studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 44 type: ESTIMATED name: XH-S003 name: Placebo measure: Number of participants with adverse events (AEs) measure: Number of participants with adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Beijing Friendship Hospital,Capital Medical University city: Beijing country: China name: Ruihua Dong, MD role: CONTACT phone: 010-63139033 email: Ruihua_Dong_RW@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06272734 id: RCV-0007 briefTitle: Reprieve System Pilot Study overallStatus: RECRUITING date: 2024-01-23 date: 2024-12-31 date: 2025-01-31 date: 2024-02-22 date: 2024-02-22 name: Reprieve Cardiovascular, Inc class: INDUSTRY briefSummary: The objective of the study is to evaluate the use of the Reprieve System to decongest subjects with acute decompensated heart failure. conditions: Acute Decompensated Heart Failure studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Reprieve System measure: Functional Device Success sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tbilisi Heart and Vascular Clinic status: RECRUITING city: Tbilisi zip: 0159 country: Georgia name: Tamaz Shaburishvili, MD role: CONTACT phone: +995 322 479300 email: tamaz_shaburishvili@yahoo.com lat: 41.69411 lon: 44.83368 hasResults: False
nctId: NCT06272721 id: 6272 briefTitle: Hypothyroidism in Pregnancy and Neuropsychological Development in Children acronym: OHPLDO overallStatus: NOT_YET_RECRUITING date: 2024-02-19 date: 2024-04-30 date: 2024-05-31 date: 2024-02-22 date: 2024-02-22 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Thyroid dysfunction, particularly hypothyroidism and thyroid autoimmunity, impacts a significant proportion of pregnant women, affecting 3% and 17% respectively. The management of thyroid-stimulating hormone (TSH) levels is crucial, with subclinical hypothyroidism often defined by a TSH upper reference limit of 4 mU/L, and overt hypothyroidism by TSH levels above 10 mU/L and potentially low free thyroxine (FT4) levels. Levothyroxine (LT4) treatment is strongly advised for TSH levels above 10 mU/L, with the timing of intervention being critical during the first trimester for optimal fetal brain development.
This study aims to explore the effects of treated maternal hypothyroidism during pregnancy on children's neurodevelopment, focusing on learning and language. It includes 31 women diagnosed with hypothyroidism and a control group of 21 euthyroid women, along with their children. The study emphasizes the importance of early detection and treatment of maternal hypothyroidism for preventing adverse neurodevelopmental outcomes in offspring. Statistical analysis will be conducted using SPSS, with a focus on maternal-fetal outcomes and cognitive-neuropsychological outcomes, highlighting the significance of early intervention. conditions: Thyroid Dysfunction conditions: Pregnancy Related conditions: Language Development studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 104 type: ESTIMATED name: Griffiths Scale measure: total development quotient measured using the Griffiths scale sex: ALL minimumAge: 2 Years maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS city: Roma zip: 00168 country: Italy name: ALFREDO PONTECORVI role: CONTACT phone: +390630155701 email: alfredo.pontecorvi@policlinicogemelli.it name: ALFREDO PONTECORVI role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06272708 id: IIT-2023-0356 briefTitle: Preliminary Exploration of Thromboelastography in the Monitoring of Anticoagulation in Maintenance Hemodialysis Patients overallStatus: RECRUITING date: 2024-01-29 date: 2024-02-29 date: 2024-05-31 date: 2024-02-22 date: 2024-02-22 name: RenJi Hospital class: OTHER briefSummary: Objectives: To investigate the role of thromboelastography parameters (R, K, Angle, MA) in monitoring anticoagulation in maintenance hemodialysis (MHD) patients.
Secondary outcome: Relationship between thromboelastography parameters (K Value, Angle and MA) and coagulation of hemodialysis circuit and dialyzer. conditions: Thromboelastography conditions: Hemodialysis conditions: Anticoagulation studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED measure: thromboelastography parameter R value measure: thromboelastography parameter K value measure: thromboelastography parameter Angle measure: thromboelastography parameter MA sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Renji Hospital, School of Medicine, Shanghai Jiao Tong University status: RECRUITING city: Shanghai state: Shanghai zip: 200127 country: China name: Yunyue Guo role: CONTACT phone: 0086-021-68383312 email: guoyunyue@renji.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06272695 id: R477-203 briefTitle: Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab overallStatus: RECRUITING date: 2024-02-15 date: 2025-06-15 date: 2025-06-15 date: 2024-02-22 date: 2024-04-10 name: REMD Biotherapeutics, Inc. class: INDUSTRY briefSummary: This trial is designed to evaluate the effect of glucagon receptor antagonism by volagidemab (once weekly) on glucose recovery from hypoglycemia after treatment with glucagon in adults with type 1 diabetes. After informed consent, Screening procedures to establish subject eligibility will be performed within a period of 28 days. Approximately 24 subjects with type 1 diabetes mellitus (T1DM) on stable doses of insulin will be enrolled.
After enrollment, subjects will undergo a baseline Hypoglycemia Recovery Procedure (with glucagon rescue). Subjects will then receive volagidemab subcutaneously (SC) once weekly for 6 weeks. At the end of the treatment phase, subjects will undergo a second Hypoglycemia Recovery Procedure. Subjects will be followed for 6 weeks after the last volagidemab dose with a final End-of-Study (EOS) visit during Week 12. The primary outcome will be the change in time to glucagon treatment success at Week 6 versus baseline. conditions: Type 1 Diabetes Mellitus studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Volagidemab measure: Change in Time to glucagon treatment success at Week 6. measure: Blood glucose response to glucagon rescue treatment during insulin-induced hypoglycemia. measure: Treatment emergent adverse events (AEs) measure: Hypoglycemia symptoms - Edinburgh Hypoglycemia Scale measure: Hypoglycemia symptoms - Clarke Survey measure: Hypoglycemia symptoms - Gold Questionnaire measure: Change from baseline in hemoglobin A1c (HbA1c) at Week 6. sex: ALL minimumAge: 18 Years maximumAge: 72 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Altman Clinical and Translational Research Institute status: NOT_YET_RECRUITING city: San Diego state: California zip: 92037 country: United States name: Schafer Boeder, MD role: CONTACT name: Schafer Baoder, MD role: PRINCIPAL_INVESTIGATOR lat: 32.71533 lon: -117.15726 facility: Diablo Clinical Research status: RECRUITING city: Walnut Creek state: California zip: 94598 country: United States name: Mark Christiansen, MD role: CONTACT email: mchristiansen@diabloclinical.com name: Mark Christiansen, MD role: PRINCIPAL_INVESTIGATOR lat: 37.90631 lon: -122.06496 hasResults: False
nctId: NCT06272682 id: 6669 briefTitle: Corticosteroids in Carpal Tunnel Syndrome. Prospective Randomised Controlled Non-inferiority Study overallStatus: RECRUITING date: 2023-07-17 date: 2024-08-11 date: 2025-10-11 date: 2024-02-22 date: 2024-02-22 name: Hospital Italiano de Buenos Aires class: OTHER briefSummary: The goal of this prospective, randomised, controlled, non-inferiority analytical study is to compare the Boston score in patients treated with systemic (intramuscular) versus local infiltration corticosteroids in mild and moderate carpal tunnel syndrome in patients over 18 years of age with mild or moderate carpal tunnel syndrome.
* Compare the pain at the site of application associated with the route of administration. conditions: Carpal Tunnel Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, randomised, controlled, non-inferiority analytical study primaryPurpose: TREATMENT masking: NONE count: 106 type: ESTIMATED name: Systemic bethametasone injection name: Local bethametasone injection measure: Compare the Boston Carpal Tunnel Syndrome Questionnaire measure: Adverse reactions measure: Pain at the site of application sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Italiano de Buenos Aires status: RECRUITING city: Buenos Aires zip: C1199 country: Argentina name: Jorge Boretto, MD role: CONTACT phone: +541169026969 email: jorge.boretto@hospitalitaliano.org.ar name: Rocio Avanzi, MD role: CONTACT phone: +541157727055 email: rocio.avanzi@hospitalitaliano.org.ar lat: -34.61315 lon: -58.37723 hasResults: False